Sunday 18 October 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022. In the quarter to June 2026, revenue fell 57.1%, EPS grew 99.5% and free cash flow grew 167.7%, each against the same quarter a year earlier.
2.68
0.48
−15.19%
Follow IBO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 14.68 | 4.58 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 41.14 | 78.10 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 5 | 8 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | 100.00 | — | — | (1,225.00) | |||||
| EBT | — | — | — | — | — | — | (8) | (4) | (25) | (14) | |||||
| EBT margin, % | — | — | — | — | — | — | (15,752.00) | 0.00 | 0.00 | (45,156.25) | |||||
| Net income | — | — | — | — | — | — | (7) | (4) | (25) | (12) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 1 | 26 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | ||||
| Earnings | — | — | — | — | — | — | (1.30) | (0.92) | (29.04) | (4.80) | |||||
| Cash flow | — | — | — | — | — | — | (0.40) | (0.60) | (3.35) | (0.76) | |||||
| Capex | — | — | — | — | — | — | (0.05) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (0.45) | (0.60) | (3.35) | (0.76) | |||||
| Book value | — | — | — | — | — | — | 5.85 | 5.92 | 8.49 | 6.23 | |||||
| Shares, m | — | — | — | — | — | — | 6 | 5 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | 194.72 | |||||
| P/B | — | — | — | — | — | — | 1.02 | — | — | 1.03 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | 291.89 | |||||
| EV/FCF | — | — | — | — | — | — | (13.50) | — | — | (12.54) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (3) | (3) | (2) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | — | — | |||||
| Free cash flow | — | — | — | — | — | — | (3) | (3) | (3) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (10) | (13) | (7) | (1) | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (2) | 0 | |||||
| Shareholders’ equity | — | — | — | — | — | — | 33 | 28 | 7 | 16 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (9.52) | (76.11) | (62.81) | ||||
| ROIC | — | — | — | — | — | — | (6.51) | (8.91) | (343.08) | (17.21) | |||||
| ROE | — | — | — | — | — | — | 0.00 | (14.25) | (139.68) | (104.15) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026
Charts ten years each
Impact Biomedical Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CVM Cel-Sci Corporation | $30.6M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $30.5M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $27.0M | 0.2× | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | |
| ATOS Atossa Therapeutics, Inc. | $26.4M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IGC IGC Pharma, Inc. | $26.3M | — (loss-making) | — (loss-making) | −19.70% (below 0%: shrinking) | n/m | −103.33% (below 0%: shrinking) | 18.11% | (1,050.57%) | Compare |
| MCRB Seres Therapeutics, Inc. | $25.2M | — (loss-making) | — (loss-making) | +96.79% (above 0%: growing) | n/m | −66.15% (below 0%: shrinking) | 100.00% | (2,890.35%) | Compare |
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $25.7M | — | — | +34.04% | — | −15.56% | 9.06% | 0.00% |
Impact Biomedical Inc. (IBO) key facts
- Concern: Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Impact Biomedical Inc. (IBO) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, IBO traded at $2.68, a market capitalization of $27.0 million.
- Return on equity was −104.2% and debt-to-equity 0.00.
- Its Altman Z-score is 0.34 (distress zone) for fiscal 2025.